Chinese Journal of Nephrology, Dialysis & Transplantation ›› 2023, Vol. 32 ›› Issue (1): 49-52.DOI: 10.3969/j.issn.1006-298X.2023.01.011
Previous Articles Next Articles
Online:
Published:
Abstract: In 2022, a lot of important progress has been made in the field of kidney disease, among which the randomized controlled trial (RCT) is still the focus of clinical attention. This paper mainly summarizes the important RCT research results in the field of kidney disease in 2022.
Key words: randomized controlled trial, kidney disease
HUANG Xianghua, ZHANG Haitao, LIU Zhihong. Highlights of randomized controlled trials on kidney disease in 2022[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2023, 32(1): 49-52.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.njcndt.com/EN/10.3969/j.issn.1006-298X.2023.01.011
http://www.njcndt.com/EN/Y2023/V32/I1/49
